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A B S T R A C T
Purpose
Treatment of oropharyngeal squamous cell carcinoma (OPSCC) is evolving toward risk-based
modification of therapeutic intensity, which requires patient-specific estimates of overall survival
(OS) and progression-free survival (PFS).
Methods
To develop and validate nomograms for OS and PFS, we used a derivation cohort of 493 patients
with OPSCC with known p16 tumor status (surrogate of human papillomavirus) and cigarette
smoking history (pack-years) randomly assigned to clinical trials using platinum-based chemo-
radiotherapy (NRG Oncology Radiation Therapy Oncology Group [RTOG] 0129 and 0522). Nomo-
grams were created from Cox models and internally validated by use of bootstrap and cross-
validation. Model discrimination was measured by calibration plots and the concordance index.
Nomograms were externally validated in a cohort of 153 patients with OPSCC randomly assigned to
a third trial, NRG Oncology RTOG 9003.
Results
Bothmodels included age, Zubrod performance status, pack-years, education, p16 status, and T and
N stage; the OS model also included anemia and age 3 pack-years interaction; and the PFS model
also included marital status, weight loss, and p16 3 Zubrod interaction. Predictions correlated well
with observed 2-year and 5-year outcomes. The uncorrected concordance index was 0.76 (95% CI,
0.72 to 0.80) for OS and 0.70 (95%CI, 0.66 to 0.74) for PFS, and bias-corrected indices were similar.
In the validation set, OS and PFS models were well calibrated, and OS and PFS were significantly
different across tertiles of nomogram scores (log-rank P = .003;, .001).
Conclusion
The validated nomograms provided useful prediction of OS and PFS for patients with OPSCC treated
with primary radiation-based therapy.
J Clin Oncol 35:4057-4065. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Tumor human papillomavirus (HPV) status is
an independent predictor of survival for patients
with oropharyngeal squamous cell carcinoma
(OPSCC).1 Indeed, the combination of tumor
HPV status, lifetime tobacco cigarette smoking
(in pack-years), and tumor and nodal stage can
be used to stratify patients into groups at high,
intermediate, or low risk of death.2,3 This NRG
Oncology Radiation Therapy Oncology Group
(RTOG) 0129 risk model is the basis of two
divergent pathways for risk-based clinical trials in
OPSCC, including therapeutic de-intensification
for the low-risk group versus therapeutic in-
tensification for the intermediate- and high-
risk groups.
Although the NRG Oncology RTOG 0129
risk model includes factors most influential for
survival, it does not account for several known
prognostic factors (eg, age, performance status).
Consequently, the survival probabilities in the
three risk groups have limited ability to predict
survival for an individual patient. Nomograms
are graphic depictions of models that can be used
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to estimate a numeric probability of an event (eg, death or pro-
gression) for an individual patient. An additional advantage of
a nomogram relative to the RTOG 0129 risk model is the ability to
provide a visual interface to aid in communication with patients.4
We developed and validated a nomogram for prediction of overall
survival (OS) and progression-free survival (PFS) for patients with
local-regionally advanced OPSCC treated with primary radio-
therapy with or without concurrent chemotherapy, inclusive of
data from NRG Oncology RTOG 0129.
METHODS
Study Populations
The derivation cohort consisted of patients with OPSCC with known
tumor p16 status and smoking history (measured in pack-years) who were
randomly assigned to two clinical trials conducted by the NRG Oncology
RTOG, 0129 and 0522.2,5,6 NRGOncology RTOG 0129 was a phase III trial
that evaluated standard fractionation versus accelerated fractionation
(AFX) radiotherapy concurrent with cisplatin. NRGOncology RTOG 0522
was a phase III trial that evaluated the addition of cetuximab to AFX
radiotherapy concurrent with cisplatin. Eligible patients had untreated,
pathologically confirmed, American Joint Committee on Cancer (AJCC)
5th edition (RTOG 0129) or 6th edition (RTOG 0522) stage III to IV7 head
and neck squamous cell carcinoma, Zubrod performance status of 0 to 1,
age $ 18 years, and adequate bone marrow, hepatic, and renal function.
The validation cohort consisted of patients with OPSCC with known
tumor p16 status and smoking history who were randomly assigned to
NRG Oncology RTOG 9003, a phase III trial that evaluated standard
fractionation versus concomitant boost versus split-course AFX versus
hyperfractionation.8 Eligible patients had untreated, pathologically con-
firmed, stage II to IV7 head and neck squamous cell carcinoma, Zubrod
performance status of 0 to 2, and age $ 18 years.
History of cigarette smoking in pack-years was obtained at enrollment
by an interviewer-administered questionnaire. Patients were followed pro-
spectively to assess disease status with physical examination and imaging studies
performed quarterly for 2 years, biannually through year 5, and then annually.
Tumor p16 expression was evaluated by immunohistochemistry
using a mouse monoclonal antibody (MTM Laboratories, Heidelberg,
Germany), visualized with the Ventana XT autostainer using the one-view
secondary detection kit (Ventana Medical Systems, Tucson, AZ).9 Tumor
p16 expression was scored as positive if strong and diffuse nuclear and
cytoplasmic staining was present in $ 70% of the tumor cells.10,11 Testing
and interpretation were centralized. P16 tumor status is a reliable surrogate
for HPV tumor detection in the oropharynx.10 Protocol approval was
received from the institutional review board at each study site, and in-
formed consent was obtained from each patient before participation.
Statistical Analysis
The demographic and clinical characteristics of patients in NRG
Oncology RTOG 0129 and 0522 included and excluded from the analysis
were compared by Fisher’s exact test. The principal outcomes of interest
included the predicted probability of 2-year or 5-year overall OS or PFS on
the basis of baseline characteristics. OS and PFS were defined, respectively,
as time from date of randomization to death from any cause and to local,
regional, or distant progression or death from any cause. The distributions
of OS and PFS were estimated by the Kaplan-Meier method12 and
compared by log-rank test stratified by trial.13 Cox proportional hazards
models14 (stratified by trial) were used to estimate hazard ratios and
95% CIs. Baseline prognostic factors of interest included age, gender,
race, marital status, education, Zubrod performance status, anemia,
tobacco pack-years, primary tumor subsite, T stage, N stage, comorbidity
score, weight loss, gastric tube placement, and tumor p16 status. Cat-
egorical variables were included in our analysis to align with the prior
literature. Given the significant influence of the RTOG 0129 recursive
partitioning analysis, cigarette smoking was categorized consistent with
that model.2 In addition, data regarding weight loss was collected as
a categorical variable, and anemia was defined as a hemoglobin level
# 13.5 g/dL for men and # 12.5 g/dL for women per RTOG 9903.15 All
two-way interactions were evaluated, and final models for OS and PFS
were selected based on clinical judgment and by comparison of Akaike
information criterion. The final OS and PFS models were internally
validated by use of bootstrap with 200 or 400 resamples and cross-
validation methods leaving 10 or 20 samples out at each iteration and
served as the basis for creation of the nomograms.16 As is standard, points
assigned to each variable included in the nomogram were assigned
proportional to the effect size.
The accuracy of predictions was evaluated by estimating the model’s
calibration, and discrimination was measured by the concordance index
(C-index).16 The C-index is the probability that for two randomly selected
patients, the patient who experienced the event first had a higher prob-
ability of having the event according to the model. A C-index of 0.5
represents agreement by chance alone, and a C-index of 1 means perfect
discrimination.
A validation cohort from NRG Oncology RTOG 9003 was used to
externally validate the models. A total risk score was calculated for each
patient in the combined cohort of NRG Oncology RTOG 0129 and 0522.
Tertiles of the total risk scores were then used to classify patients fromNRG
Oncology RTOG 9003 into three groups. The Cox model was used to
compare whether the survival distributions differed among the three risk
groups. All analyses were performed using SAS (SAS Institute, Cary, NC)
and R 3.2.3. All P are two-sided and multiple comparisons are adjusted
based on the Westfall method.17
RESULTS
Derivation Cohort
A total of 493 of 1,058 patients with OPSCC treated in NRG
Oncology RTOG 0129 and NRGOncology RTOG 0522 had known
tumor p16 tumor status and pack-years of cigarette smoking and
therefore comprised the derivation cohort (Appendix Fig A1,
online only). Patients included were similar to patients excluded
from the analysis, with the exception that in RTOG 0129, they were
significantly less likely to have p16-negative tumors (Data Sup-
plement). The baseline characteristics of the derivation and vali-
dation cohorts are listed in Table 1.
Overall Survival
Median follow-up was 8.0 years (95% CI, 7.9 to 8.1 years) in
NRG Oncology RTOG 0129, 4.8 years (95% CI, 4.5 to 5.0 years) in
NRG Oncology RTOG 0522, and 5.7 years (95% CI, 5.2 to 6.0
years) for the derivation cohort. A total of 151 deaths occurred
during follow-up. Estimated 2-year and 5-year OS were 83.6%
(95% CI, 80.0% to 86.6%) and 72.0% (95% CI, 67.6% to 75.8%),
respectively.
The final model for OS is listed in Table 2. In multivariable
analysis, factors found to be significantly associated with OS
included age, cigarette smoking pack-years, Zubrod performance
status, education, anemia, tumor p16 tumor status, Tstage, and N
stage. A significant interaction was observed between age and
tobacco pack-years (P-interaction = .02). Age older than 50 years
significantly increased the risk of death for individuals with # 10
pack-years (hazard ratio [HR], 5.94; 95% CI, 2.11 to 16.70;
P , .001), but not . 10 pack-years (HR, 1.55; 95% CI, 0.96 to
4058 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
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2.51; P = .07) of tobacco exposure. Moreover,. 10 pack-years of
tobacco exposure significantly increased the risk of death for
individuals # 50 years of age (HR, 4.81; 95% CI, 1.64 to 14.11;
P = .004), but not . 50 years (HR, 1.26; 95% CI, 0.84 to 1.89;
P = .27).
Figure 1A shows the calibration plot for the OS model, in
which the predicted probability of 5-year OS is plotted against the
observed data. Modeled 5-year estimates of OS closely approxi-
mated the observed estimates, but deviated slightly among in-
dividuals with poor survival. Model discrimination was evaluated
with the C-index, which quantifies the level of concordance be-
tween the predicted and observed OS (Data Supplement). The
C-index for the final OS model was 0.76 (95% CI, 0.72 to 0.80).
The bias corrected C-indices generated by bootstrap validations
were 0.74 (95% CI, 0.70 to 0.78) and 0.75 (95% CI, 0.71 to 0.79),
with 20-fold internal cross-validation similar to that of 10-fold
internal cross-validation, arguing against an overfit model.
The internally validated model was used to create a nomo-
gram to estimate the predicted probability of 2-year or 5-year OS
(Fig 1B). The nomogram is a graphic depiction of the model, in
which points are assigned based on the rank order of the effect
estimates. Factors assigned the highest number of points included
age, smoking, and tumor p16 status. For example, a 45-year-old
male smoker (12 pack-years) with a Zubrod performance status of
0, no high school education, and no anemia, diagnosed with p16-
positive, AJCC 7th edition stage T2N2bM0 OPSCC would have
a total of 101 points and an estimated 2-year and 5-year OS of 94%
(95% CI, 0.90% to 0.97%) and 87% (95% CI, 0.81% to 0.94%),
respectively. As shown in Figure 1C, the predicted probability of
2-year and 5-year OS declined as a function of the total number of
points generated by use of the nomogram. The predictive accuracy
of the OS nomogram was compared with the original NRG
Oncology RTOG 0129 risk stratification model, which had
a C-index for OS of 0.71 (95% CI, 0.66 to 0.76), indicating
modestly improved accuracy in predicting survival with the
nomogram.
Progression-Free Survival
Estimated 2-year and 5-year PFS rates were 69.7% (95% CI,
65.4% to 73.6%) and 61.1% (95%CI, 56.6% to 65.3%), respectively.
A total of 201 events occurred during follow-up.
Factors independently associated with PFS in multivariable
analysis included age, Zubrod performance status, p16 status, weight
loss, education, marital status, pack-years, T stage, and N stage
(Table 2). A significant interaction was observed between perfor-
mance status and tumor p16 status (P = .02). A performance status
of 1 significantly increased the risk of progression/death for patients
with p16-positive tumors (HR, 2.05; 95%CI, 1.39 to 3.01; P, .001),
but not p16-negative tumors (HR, 1.03; 95% CI, 0.66 to 1.61;
P = .89). Moreover, patients with p16-negative tumors had a signif-
icantly increased risk of progression/death if their performance status
was 0 (HR, 2.26; 95% CI, 1.53 to 3.36; P , .001), but not if their
performance status was 1 (HR, 1.14; 95% CI, 0.73 to 1.79; P = .57).
The PFS model was well calibrated (Fig 2A) and had an
uncorrected C-index of 0.70 (95%CI, 0.66 to 0.74). The bootstrap-
corrected C-index was 0.68 (95% CI, 0.64 to 0.72) and was similar
after bias correction, with 10-fold (0.68; 95% CI, 0.64 to 0.72) and
20-fold (0.69; 95% CI, 0.65 to 0.73) cross-validation (Data Sup-
plement). The nomogram for PFS built on this final, internally
validated model is shown in Fig 2B. As for OS, PFS decreased with
increasing number of total points (Fig 2C).
External Validation
To evaluate the OS and PFS nomograms generated in the
derivation cohort, the models were applied to a validation cohort
of 153 patients with OPSCC in NRG Oncology RTOG 9003
(CONSORT diagram; Appendix Fig A2, online only). The median
follow-up time was 16.1 years (95% CI, 15.1 to 17.7 years), with
136 and 140 OS and PFS events, respectively. The characteristics of
the validation cohort are listed in Table 1. The OS model as applied
to the validation cohort had an uncorrected C-index of 0.68 (95%
CI, 0.63 to 0.73) and a bootstrap-corrected C-index of 0.64 (95%
CI, 0.59 to 0.69) with 400 resamples. A total risk score was cal-
culated for each patient in the combined cohort of RTOG 0129 and
Table 1. Characteristics of the Study Population
Characteristic
Derivation Cohort
RTOG 0129/0522
(n = 493)
No. (%)
Validation Cohort
RTOG 9003
(n = 153)
No. (%)
Age (years)
# 50 136 (27.6) 39 (25.5)
. 50 357 (72.4) 114 (74.5)
Gender
Female 62 (12.6) 34 (22.2)
Male 431 (87.4) 119 (77.8)
Education
Some college/vocational/
technical school or more
268 (54.4) 46 (30.1)
High school graduate or less 225 (45.6) 107 (69.9)
Marital status
Married or with live-in partner 326 (66.1) 79 (51.6)
Single/divorced/separated/
widowed
167 (33.9) 74 (48.4)
Zubrod performance status
0 340 (69.0) 101 (66.0)
1 153 (31.0) 52 (34.0)
Smoking history (pack-years)
# 10 233 (47.3) 32 (20.9)
. 10 260 (52.7) 121 (79.1)
Weight loss in past 6 months
, 5% 354 (71.8) 86 (56.2)
$ 5% 139 (28.2) 67 (43.8)
Anemic*
No 364 (73.8) 92 (60.1)
Yes 129 (26.2) 61 (39.9)
p16 status
Positive 363 (73.6) 63 (41.2)
Negative 130 (26.4) 90 (58.8)
T stage†
T2-3 355 (72.0) 117 (76.5)
T4 138 (28.0) 36 (23.5)
N stage
7th edition N0-2b/8th edition
N0-N1
328 (66.5) 108 (70.6)
7th edition N2c-3/8th edition
N2-N3
165 (33.5) 45 (29.4)
NOTE: 7th edition and 8th edition refer to the American Joint Commission on
Cancer staging system.
Abbreviation: RTOG, Radiation Therapy Oncology Group.
*Defined as hemoglobin level# 13.5 g/dL for men and# 12.5 g/dL for women.
†Tumor stage by 7th and 8th edition of American Joint Committee on Cancer
staging system.
jco.org © 2017 by American Society of Clinical Oncology 4059
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0522. Tertiles of the total risk scores were then used to classify
patients from RTOG 9003 into three groups. OS was significantly
different across tertiles of nomogram scores (Fig 3A; log-rank
P = .003; P, .001 for the combined cohort). Median OS times for
patients in the lower, middle, and upper tertiles were 7.33 years
(95% CI, 4.8 to 14.9 years), 3.24 years (95% CI, 1.88 to 5.84 years),
and 1.37 years (95% CI, 1.20 to 2.24 years), respectively.
The PFS model in the validation cohort had an uncorrected
C-index of 0.68 (95% CI, 0.64 to 0.72) and a bootstrap-corrected
C-index of 0.64 (95% CI, 0.60 to 0.68). Median PFS times for
patients in the lower, middle, and upper tertiles were 12.8 years
(95% CI, 5.08 years to not available), 1.81 years (95% CI, 1.13 to
3.40 years) and 0.85 years (95% CI, 0.72 to 1.5 years), respectively
(Fig 3B; log-rank P , .001; P , .001 for the combined cohort).
DISCUSSION
We developed and validated nomograms to predict 2-year and
5-year OS and PFS for patients with locoregionally advanced
OPSCC treated with primary radiation-based therapy. Notably, the
nomograms permit integration of clinical, pathologic, and social
risk factors and their interactions that affect survival. Most importantly,
the nomograms provide personalized, patient-specific estimates of OS
and PFS that can be used for risk-stratification and discussions of
prognosis with patients.
Our internally and externally validated nomograms have some
similarities with and potential advantages over two previously
published nomograms for OPSCC.18,19 Several predictive factors in
our nomogram were common with the well-validated nomogram
published by Rios Velasquez et al18 (anemia, smoking, T stage, N
stage, HPV status), but our larger sample size, longer follow-up time,
and prospective data collection allowed us to evaluate the contri-
bution of additional factors as well as to create separate nomograms
for 2-year and 5-year OS and PFS outcomes.2,18-20Wewere unable to
evaluate the relative performance of the Rios Velasquez model in our
derivation cohort because of the absence of data for the Adult
Comorbidity Evaluation-27. Shoultz-Henley et al19 developed a no-
mogram that included thrombocytosis as an independent factor for 5-
year OS (in addition to HPV status, stage, and anemia), but the model
was neither internally nor externally validated. Unfortunately, platelet
counts were not collected at baseline in our derivation cohort.
We acknowledge that the new prognostic nomograms provide
only modest improvements in discrimination over the RTOG 0129
risk model, as indicated by a comparison of the C-index for
both models. Although the RTOG 0129 recursive partitioning
Table 2. Overall and Progression-Free Survival Models for Nomograms
End Point/Variable Hazard Ratio 95% CI P
Overall survival
Age (. 50 v # 50 years) — — , .001
If # 10 pack-years 5.94 2.11 to 16.70 –
If . 10 pack-years 1.55 0.96 to 2.51 –
Pack-years (. 10 v # 10) — — .004
If age # 50 years 4.81 1.64 to 14.11 –
If age . 50 years 1.26 0.84 to 1.89 –
Age 3 pack-years interaction — — .02
Zubrod performance status (1 v 0) 1.62 1.16 to 2.26 .005
Education (high school or less v others) 1.59 1.12 to 2.26 .01
Anemic (yes v no) 1.46 1.04 to 2.06 .03
p16 status (negative v positive) 2.31 1.63 to 3.26 , .001
T stage (T4 v T2-3) 1.84 1.33 to 2.56 , .001
N stage (7th edition N2c-3 v N0-2b; 8th edition N2-N3 v N0-N1) 1.76 1.27 to 2.45 , .001
AIC: 1464.32
C-index original: 0.76
Bootstrap C-index: 0.75
Progression-free survival
Age (. 50 v # 50 years) 1.74 1.22 to 2.47 .002
Zubrod performance status (1 v. 0) — — , .001
If p16-positive 2.05 1.39 to 3.01 —
If p16-negative 1.03 0.66 to 1.61 —
p16 status (negative v positive) — — , .001
If Zubrod 0 2.26 1.53 to 3.36 —
If Zubrod 1 1.14 0.73 to 1.79 —
Zubrod 3 p16 status interaction — — .02
Weight loss ($ 5% v , 5%) 1.40 1.02 to 1.91 .04
Education (high school or less v others) 1.47 1.09 to 1.98 .01
Marital status (no partner v partner) 1.37 1.01 to 1.84 .04
Pack-years (. 10 v # 10) 1.53 1.10 to 2.11 .01
T stage (T4 v T2-3) 1.29 0.95 to 1.75 .10
N stage (7th edition N2c-3 v N0-2b; 8th edition N2-N3 v N0-N1) 1.93 1.44 to 2.58 , .001
AIC: 1998.10
C-index original: 0.70
Bootstrap C-index: 0.68
Abbreviations: AIC, Akaike information criterion; C-index, concordance index.
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Fig 1. Overall survival (OS). (A) Calibration plot of OS at 5 years. Nomogram-predicted OS is plotted on the x-axis, with observed OS on the y-axis. Dashed lines along
the 45-degree line through the origin point represent the perfect calibration models in which the predicted probabilities are identical to the actual probabilities.
(B) Nomogram for predicting probability of OS at 2 and 5 years. The presence or absence of each clinical characteristic indicates a certain number of points. Number of
points for each clinical characteristic is on the top row. For each characteristic, the absence is assigned zero points. The presence of characteristics is associated with
number of points. The points for each characteristic are summed together to generate a total-points score. The total points correspond to respective 2-year and 5-year
OS probabilities. (C) Predicted 2-year (thick dark line with short dashed 95% CIs) and 5-year (thin dark line with long dashed 95% CIs) OS probability on the basis of
nomogram total points.
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analysis–based risk model is more parsimonious, nomograms
nevertheless offer some relative benefits.21 The former model
provides average survival estimates for a heterogeneous pa-
tient population, which may reduce the predictive accuracy of
prognostication for an individual patient. For example, the
intermediate-risk group included both p16-positive and p16-
negative patients. For individuals with survival approaching the
mean, a nomogrammay not offer improvement in prognostication.
However, for certain individuals with specific combinations of
characteristics (such as those provided in the following example)
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Fig 2. Progression-free survival (PFS). (A) Calibration plot of PFS at 5 years. Nomogram-predicted PFS is plotted on the x-axis, with observed PFS on the y-axis. Dashed
lines along the 45-degree line through the origin point represent the perfect calibrationmodels in which the predicted probabilities are identical to the actual probabilities. (B)
Nomogram for predicting probability of PFS at 2 and 5 years. The presence or absence of each clinical characteristic indicates a certain number of points. Number of points
for each clinical characteristic is on the top row. For each characteristic, the absence is assigned zero points. The presence of characteristics is associated with number of
points. The points for each characteristic are summed together to generate a total-points score. The total points correspond to respective 2-year and 5-year PFS
probabilities. (C) Predicted 2-year (thick dark line with short dashed 95%CIs) and 5-year (thin dark line with long dashed 95%CIs) PFS probability on the basis of nomogram
total points. PS, performance status.
4062 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Fakhry et al
whose survival deviates substantially from the mean, the nomogram
offers improved prognostication. In such cases, the nomogram may
provide amore tailored risk prediction. Further studies are needed to
determine whether the inclusion of continuous variables to the model
could enhance personalization. A strength of this article over the
original RTOG0129model is the internal and external validation of the
model. Moreover, the nomograms permit the inclusion of additional
prognostic variables that can alter survival estimateswhen tailored to an
individual patient’s characteristics. For example, a 60-year-old non-
smoker diagnosed with HPV-positive, AJCC 7th edition stage T4N2b
OPSCCwould have a 2-yearOS of 95%on the basis of the RTOG0129
risk model. Knowledge that he or she is also an unmarried high school
graduate who presents with a Zubrod performance status of 1, . 5%
weight loss, and anemia results in an estimated 2-year OS of 70% per
the nomogram. This example highlights some limitations of the more
parsimonious RTOG 0129 model. The differences in the estimates for
OS in this case may alter a patient’s and physician’s perceptions re-
garding the appropriateness of treatment de-intensification. Additional
research will be required to determine potential thresholds for total
nomogrampoints and associated predicted probabilities ofOS and PFS
that are appropriate for use as eligibility criteria for clinical trials of
treatment de-intensification versus intensification.
Nomograms for breast, prostate, and other malignancies have
been shown to assist patients with the complex discussions regarding
the risks and benefits of treatment options.4,22-25 Illustrations have
been shown to significantly augment physician-patient communi-
cation, and nomograms provide a visual image of prognostic factors
as well as their relative influence. This facilitates active partici-
pation by patients in their treatment decisions.26 Patients can
access nomogram calculators online (eg, theWeb site of the National
Cancer Institute) and, more recently, on smartphone applications.23
Online nomogram risk calculators based upon our data are
available (https://www.nrgoncology.org/Nomograms/Oropharynx-
Cancer-Overall-Survival-Calculator; https://www.nrgoncology.org/
Nomograms/Oropharynx-Cancer-Progression-Free-Survival-
Calculator). These estimates might allow patients to determine
desired treatment intensity in the context of a personal PFS orOS estimate.
We acknowledge several limitations. We cannot exclude the
potential for bias in our model because of exclusion of a proportion
of enrolled patients as a result of missing data for key variables (eg,
smoking and p16 status). In addition, we cannot exclude the pos-
sibility of residual confounding after internal validation as a result of
possible overfitting from variable and threshold selection for these
models. However, internal validationwith bootstrapping and external
validation were used to address these concerns. Radiotherapy frac-
tionation schedules in the derivation cohort were not associated with
OS or PFS and were distinct from those included in the validation
cohort, and therefore could not be included in themodel. Of note, we
have included both AJCC 7th and 8th edition T stage and N stage
categories for OPSCC in our model labels to assist in interpretation.
Strengths of this study include external validation of the
nomograms in a patient cohort with important differences when
compared with the derivation cohort. Relative to the derivation
cohort, the validation cohort predominantly comprised smokers
with HPV-negative OPSCC (Table 1) who were treated earlier in
calendar time with radiation alone. Validation of the nomogram
in such a different cohort highlights that the nomogram is robust
because the predicted survival estimates of the nomogram were
upheld in a distinct patient cohort. Additional important dif-
ferences in RTOG 9003 include radiotherapy alone without
chemotherapy and staging before positron emission tomography
scans. Validation of the nomogram when applied to a distinct
patient population and treatment paradigm is a strength of this
analysis. However, additional validation will be required to evaluate
the nomograms’ utility among patients treated with primary surgical
resection and in other heterogeneously treated patient populations.
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Fig 3. Survival curves for validation cohort. (A) Overall survival (OS) curves for the validation cohort for the three groups defined by tertiles of the total points from the
derivation cohort (P values: first tertile versus second tertile, .05; second tertile versus third tertile, .04). (B) Progression-free survival curves for the validation cohort for the
three groups defined by tertiles of the total points from the derivation cohort (P values: first tertile versus second tertile, , .001; second tertile versus third tertile, .3).
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Enrolled in NRG Oncology RTOG 0129
(N = 743)
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(n = 493)
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(n = 433)
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(n = 4)
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(n = 2)
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  Missing other baseline variable(s) 
(n = 261)
(n = 304)
(n = 34)
(n = 26)
Fig A1. CONSORT diagram for Radiation Therapy Oncology Group (RTOG) 0129 and RTOG 0522.
Enrolled in NRG Oncology RTOG 9003
(N = 1,113)
Oropharyngeal primary site
(n = 650)
Analyzed
(n = 153)
Included in protocol analysis
Exclusions
  Did not meet protocol inclusion criteria
  Withdrew consent
  No data after random assignment
(n = 1,076)
(n = 33)
(n = 1)
(n = 3)
Included in this analysis
Exclusions
  Missing p16 status
  Missing pack-years
  Missing other baseline variable(s)
(n = 153)
(n = 460)
(n = 15)
(n = 22)
Fig A2. CONSORT diagram for Radiation Therapy Oncology Group (RTOG)
9003.
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